Acute Care Research

Each year the NHS provides 110 million unplanned, acute patient contacts, with unplanned admissions to hospital rising. The cost of acute care to the NHS is £17 billion each year. Adults and children from BAME communities and those from poorer socioeconomic areas are 50% more likely to present acutely to healthcare services and their care journey is more chaotic, associated with worse outcomes. Despite critical need, this area of healthcare has seen less innovation than any other.

The aim of the Birmingham Acute Care Research Group is to provide an evidence base for the management of acute illness across the life-course and across specialities. Compromising of a broad range of medical and surgical doctors, anaesthetists, intensivists, allied-health care professionals, discovery scientists, bioinformaticians and trialists across adults and paediatric specialities, our research spans cutting edge translational science, early to late phase clinical trials of medicines and devices and process evaluation.

Our mission:

To improve the health of patients of all ages, leading translational and clinical research in Acute Care, by working together across disciplines; linking academia, industry and the NHS.

Acute Care Research Principal Investigators

Principal Investigator	Research Interest
Professor Fang Gao	Pre-clinical, translational and clinical research in perioperative and critical care medicine
Professor David Thickett	Primary lung epithelial and macrophage biology
Dr Elizabeth Sapey	Non-communicable inflammatory diseases associated with ageing.
Dr Dhruv Parekh	Developing novel therapies in ARDS, perioperative inflammation, sepsis and critical care.
Dr Jaimin Patel	Outcomes of patients following emergency surgery, immune responses to sepsis/inflammation and acute lung injury.
Dr Babu Naidu	Mechanism, detection and therapy of post operative acute lung injury.
Dr Barney Scholefield	Early prognostic modelling of neurodevelopmental outcome for children after cardiac arrest.
Dr Aaron Scott	Respiratory inflammation in both the acute (ARDS) and chronic setting (COPD, IPF), and the development of novel therapeutics.